Sonoma Biotherapeutics Stock
HealthTechLooking to sell Sonoma Biotherapeutics stock or options?
Sonoma Biotherapeutics develops T-cell therapies with the aim of treating autoimmune and degenerative diseases. The company's therapies work by promoting self-tolerance, which stops the damaging inflammatory responses commonly seen in autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Additionally, it offers potential treatment options for degenerative diseases such as amyotrophic lateral sclerosis and Alzheimer's, thus providing physicians with new ways to combat these critical illnesses.
Osage University Partners, Regeneron Pharmaceuticals, Octagon Capital Advisors, Mirae Asset Capital, Frazier Healthcare Partners, Timefolio Capital, Deep Track Capital, Piper Sandler, Ally Bridge Group, Fidelity Management & Research Company, ARCH Venture Partners, ArrowMark Partners, Paratus Investment, Lilly Asia Ventures, GV, Avidity Partners, Janus Henderson Investors, Casdin Capital, T1D Fund, Vertex Ventures HC, Mirae Asset Global Investments, 8VC, Lyell Immunopharma, Lifeforce Capital, Alexandria Venture Investments.